JP6983221B2 - 大腸癌の併用検査 - Google Patents

大腸癌の併用検査 Download PDF

Info

Publication number
JP6983221B2
JP6983221B2 JP2019503672A JP2019503672A JP6983221B2 JP 6983221 B2 JP6983221 B2 JP 6983221B2 JP 2019503672 A JP2019503672 A JP 2019503672A JP 2019503672 A JP2019503672 A JP 2019503672A JP 6983221 B2 JP6983221 B2 JP 6983221B2
Authority
JP
Japan
Prior art keywords
crc
patient
colonoscopy
nucleosome
stool
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019503672A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019527361A (ja
JP2019527361A5 (https=
Inventor
ビンセント ミカレフ ジャコブ
テレル ジェイソン
Original Assignee
ベルジアン ボリション エスピーアールエル
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベルジアン ボリション エスピーアールエル filed Critical ベルジアン ボリション エスピーアールエル
Publication of JP2019527361A publication Critical patent/JP2019527361A/ja
Publication of JP2019527361A5 publication Critical patent/JP2019527361A5/ja
Application granted granted Critical
Publication of JP6983221B2 publication Critical patent/JP6983221B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019503672A 2016-07-25 2017-07-25 大腸癌の併用検査 Active JP6983221B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1612815.9A GB201612815D0 (en) 2016-07-25 2016-07-25 Novel combination test
GB1612815.9 2016-07-25
PCT/EP2017/068754 WO2018019827A1 (en) 2016-07-25 2017-07-25 Combination test for colorectal cancer

Publications (3)

Publication Number Publication Date
JP2019527361A JP2019527361A (ja) 2019-09-26
JP2019527361A5 JP2019527361A5 (https=) 2020-08-20
JP6983221B2 true JP6983221B2 (ja) 2021-12-17

Family

ID=56894403

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503672A Active JP6983221B2 (ja) 2016-07-25 2017-07-25 大腸癌の併用検査

Country Status (16)

Country Link
US (1) US20200182875A1 (https=)
EP (1) EP3488238B1 (https=)
JP (1) JP6983221B2 (https=)
KR (1) KR102442803B1 (https=)
CN (1) CN109791154A (https=)
AU (1) AU2017301970B2 (https=)
BR (1) BR112019001384A2 (https=)
CA (1) CA3031580A1 (https=)
GB (1) GB201612815D0 (https=)
IL (1) IL264359B2 (https=)
MY (1) MY193895A (https=)
RU (1) RU2019104870A (https=)
SG (2) SG10202100630SA (https=)
TW (1) TWI776816B (https=)
WO (1) WO2018019827A1 (https=)
ZA (1) ZA201808601B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201906199D0 (en) * 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
WO2021024009A1 (en) * 2019-08-02 2021-02-11 Shanghai Yunxiang Medical Technology Co., Ltd. Methods and compositions for providing colon cancer assessment using protein biomarkers
CN112345766B (zh) * 2020-10-22 2024-02-02 中国工程物理研究院核物理与化学研究所 一种荧光-放射性联用的体外靶向筛选方法
TW202242146A (zh) * 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
EP4291899A1 (en) * 2021-02-11 2023-12-20 EDP Biotech Corporation Kits and methods for detecting markers and determining the presence or risk of cancer
WO2024223947A1 (en) * 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
CN116973572B (zh) * 2023-06-02 2025-03-07 东南大学附属中大医院 基于血、粪便铁蛋白检测评估肠屏障损伤严重程度的方法
CN116718775B (zh) * 2023-08-04 2023-10-27 天津迈基生物科技有限公司 一种检测结直肠癌的组合物、试纸及方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2541178T3 (es) * 2009-02-03 2015-07-16 Mdxhealth Sa Método de detección de cáncer colorrectal
WO2010120942A2 (en) * 2009-04-14 2010-10-21 The Regents Of The University Of California Histone modification patterns for clinical diagnosis and prognosis of cancer
US8568984B2 (en) * 2010-02-19 2013-10-29 Philadelphia Health & Education Corporation Methods of diagnosing non-urinary tract diseases by detecting aberrant methylation
JP2012018119A (ja) * 2010-07-09 2012-01-26 Toray Ind Inc 大腸癌検出用マーカーおよびそれを用いた大腸癌検出方法
CN103328500B (zh) * 2010-08-04 2018-01-26 西兹尔生物技术有限公司 用于癌症的诊断和治疗的方法和化合物
GB201115098D0 (en) * 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
PT2788767T (pt) * 2011-12-07 2017-12-06 Belgian Volition Sprl Método de detecção de adutos de nucleosoma
EP4001436B1 (en) * 2012-05-11 2024-03-13 Clinical Genomics Pty. Ltd. Diagnostic gene marker panel

Also Published As

Publication number Publication date
MY193895A (en) 2022-10-31
IL264359B2 (en) 2024-03-01
EP3488238B1 (en) 2023-06-07
TW201804156A (zh) 2018-02-01
TWI776816B (zh) 2022-09-11
IL264359B1 (en) 2023-11-01
AU2017301970A1 (en) 2019-01-17
KR102442803B1 (ko) 2022-09-15
CN109791154A (zh) 2019-05-21
BR112019001384A2 (pt) 2019-04-30
US20200182875A1 (en) 2020-06-11
RU2019104870A (ru) 2020-08-25
IL264359A (en) 2019-02-28
EP3488238A1 (en) 2019-05-29
ZA201808601B (en) 2019-09-25
WO2018019827A1 (en) 2018-02-01
GB201612815D0 (en) 2016-09-07
EP3488238C0 (en) 2023-06-07
JP2019527361A (ja) 2019-09-26
SG11201900329XA (en) 2019-02-27
KR20190039089A (ko) 2019-04-10
AU2017301970B2 (en) 2023-04-27
RU2019104870A3 (https=) 2020-12-01
SG10202100630SA (en) 2021-03-30
CA3031580A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
JP6983221B2 (ja) 大腸癌の併用検査
JP6263474B2 (ja) ヌクレオソームアダクト検出法
JP7094700B2 (ja) 喀痰試料中のバイオマーカーとしての細胞外遊離ヌクレオソームの使用
JP2014531573A (ja) ヌクレオチド含有ヌクレオソーム検出法
JP6777757B2 (ja) 癌検出のためのヌクレオソーム−転写因子複合体の使用
CA3208089A1 (en) Method for the detection of lung cancer
WO2019122341A1 (en) Method for the detection and treatment of colorectal adenomas
EP3317672B1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
EP3963331B1 (en) Method for the detection of cancer
WO2024223947A1 (en) Use of cell free nucleosomes as biomarkers of carcinomas
KR20240068432A (ko) 혈액 내 단백질 바이오마커를 포함하는 암 진단용 키트
HK40055426A (en) Use of dna-transcription factor complexes for cancer detection
HK1255090A1 (en) Use of cell-free nucleosomes as biomarkers in fecal samples
HK1255090B (en) Use of cell-free nucleosomes as biomarkers in fecal samples

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200707

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200707

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210324

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210330

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210628

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211102

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211122

R150 Certificate of patent or registration of utility model

Ref document number: 6983221

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250